Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7776256 | 0.90 | TP53 (0.49) | L3MBTL1KDM4EPKMPOLBGAA | |
| SCHEMBL7776564 | 0.88 | — | — | |
| SCHEMBL7776541 | 0.88 | — | — | |
| SCHEMBL7774801 | 0.88 | TP53 (0.47) | L3MBTL1KDM4EPKMPOLBGAA | |
| SCHEMBL7776418 | 0.87 | BRD4 (0.45) | — | |
| SCHEMBL7774882 | 0.87 | BRD4 (0.45) | — | |
| SCHEMBL7774780 | 0.87 | MEN1 (0.44) | — | |
| SCHEMBL7774894 | 0.87 | L3MBTL1 (0.50) | L3MBTL1KDM4EPKMPOLBGAA | |
| SCHEMBL7770160 | 0.86 | L3MBTL1 (0.41) | L3MBTL1KDM4EPKMPOLBLMNA | |
| SCHEMBL7770192 | 0.86 | BRD4 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1125936-A2 | Aryl substituted azabenzimidazoles and their use in the treatment of HIV and AIDS related diseases | Pfizer Products Inc. (US) | 2001-08-22 | — | — | EP | claimed |
| US-6242461-B1 | Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases | PFIZER INC. | 2001-06-05 | — | — | US | claimed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| JP-2004002483-A | ARYL-SUBSTITUTED AZABENZIMIDAZOLE | PFIZER PROD INC | 2004-01-08 | — | — | JP | disclosed |
| EP-1125936-A2 | Aryl substituted azabenzimidazoles and their use in the treatment of HIV and AIDS related diseases | Pfizer Products Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| JP-2001226374-A | AZABENZIMIDAZOLE HAVING ARYL SUBSTITUENT, AND ITS APPLICATION TO THERAPY OF HIV AND AIDS-ASSOCIATED DISEASES | PFIZER PROD INC | 2001-08-21 | — | — | JP | disclosed |
| US-6242461-B1 | Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases | PFIZER INC. | 2001-06-05 | — | — | US | disclosed |